Pay in 4 interest-free payments of $7.16 Learn more
Ships within 48 hours · Estimated delivery Nov 3 - Nov 8
According to research shared by the Diabetes in Control community, early findings suggest modest improvements in glycemic variability
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Current research is heavily focused on quantifying these benefits in conditions such as type 2 diabetes (T2D), metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), and associated cardiovascular risk factors
The tolerable upper intake level set by the Institute of Medicine is 100 mg per day for adults, and the compounded dose is a small fraction of that
US$ 23.82
US$ 28.29
US$ 27.81
US$ 22.14
US$ 29.44
US$ 21.44
